Nelfinavir: fourth protease inhibitor approved

Crit Path AIDS Proj. 1997 Summer:(No 32):31-2.

Abstract

AIDS: The Food and Drug Administration (FDA) has granted accelerated approval to nelfinavir in both adult and pediatric formulations. Agouron, the manufacturer, used innovative computerized drug design techniques to discover, design, and refine the nelfinavir molecule. Nelfinavir is marketed under the trade name Viracept, and costs $5,000 per year. Early clinical trials find it to be as powerful as the other protease inhibitors, but with a different resistance profile. The drug has relatively few drug indications; however, several compounds have been contraindicated.

Publication types

  • Newspaper Article

MeSH terms

  • Adult
  • Child
  • Drug Approval*
  • Drug Interactions
  • Drug Resistance, Microbial
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / adverse effects
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Isoquinolines / adverse effects
  • Isoquinolines / therapeutic use*
  • Nelfinavir
  • Sulfonic Acids / adverse effects
  • Sulfonic Acids / therapeutic use*
  • United States
  • United States Food and Drug Administration

Substances

  • HIV Protease Inhibitors
  • Isoquinolines
  • Sulfonic Acids
  • Nelfinavir